Aptorum Group Ltd Class A
$ 0.91
9.43%
10 Apr - close price
- Market Cap 6,772,300 USD
- Current Price $ 0.91
- High / Low $ 0.91 / 0.82
- Stock P/E N/A
- Book Value 2.84
- EPS -0.19
- Next Earning Report 2026-04-28
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.07 %
- ROE -0.11 %
- 52 Week High 4.47
- 52 Week Low 0.65
About
Aptorum Group Limited, a pharmaceutical company, is dedicated to the discovery, development and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. The company is headquartered in London, the United Kingdom.
Analyst Target Price
$80.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Mar 2025 | Sep 2024 | Mar 2023 | Jun 2022 | Mar 2022 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-12-31 | 2025-12-18 | 2025-04-30 | 2024-12-20 | 2023-04-28 | 2022-09-30 | 2022-04-29 | 2021-09-15 | 2021-04-19 | 2021-03-31 | 2020-12-31 | 2020-09-01 |
| Reported EPS | -0.0378 | -0.06 | -0.29 | -0.5 | -2.22 | -0.05 | -0.25 | -0.47 | 0.38 | -0.2346 | 0.1889 | -0.21 |
| Estimated EPS | None | None | 0 | 0 | None | -3 | -3.3 | -3 | -3.1 | 0 | 0 | 0 |
| Surprise | 0 | 0 | -0.29 | -0.5 | 0 | 2.95 | 3.05 | 2.53 | 3.48 | -0.2346 | 0.1889 | -0.21 |
| Surprise Percentage | None% | None% | None% | None% | None% | 98.3333% | 92.4242% | 84.3333% | 112.2581% | None% | None% | None% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-28 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: APM
2026-03-23 03:40:13
This article analyzes the historical performance of a $1,000 investment in Aptorum Group Ltd (APM) over various periods, showing significant losses over 5 and 10 years, but a gain in the last year. It also provides a detailed overview of Aptorum Group, a clinical-stage biopharmaceutical company focusing on oncology and infectious diseases, and elaborates on its proposed merger with DiamiR Biosciences. The merger aims to combine Aptorum's biopharmaceutical development with DiamiR's molecular diagnostics platform, focusing on brain health.
2026-03-16 06:09:02
Aptorum Group Limited filed a Form 6-K reporting the results of its 2025 annual meeting of shareholders held on March 10, 2026. The report details the voting outcomes for the re-election of Class I directors, Justin Wu and Douglas Arner, and the re-appointment of Marcum Asia CPAs LLP as independent auditors. A robust quorum was established with 96.97% of voting power represented, and no broker non-votes were recorded for either proposal.
2026-03-10 15:39:41
Aptorum Group and DiamiR Biosciences announced the publication of a study in "Diagnostics" demonstrating the feasibility of using microRNA-based blood tests to detect glioblastoma, the most aggressive and lethal form of brain cancer. This study, conducted with the University of Pennsylvania, identifies specific microRNA signatures in blood plasma that show promise as non-invasive biomarkers for diagnosis and monitoring, potentially offering an alternative to invasive biopsies or costly imaging. The findings pave the way for larger clinical studies to validate the utility of these microRNA signatures for improved patient care.
2026-03-09 09:40:10
Aptorum Group and DiamiR Biosciences have announced the publication of a study in Diagnostics detailing the development of microRNA-based glioblastoma biomarkers. This research, conducted with the University of Pennsylvania, outlines a minimally invasive blood plasma test for detecting glioblastoma, the most aggressive form of brain cancer. The findings show promise for earlier diagnosis and improved patient monitoring through specific microRNA signatures.
2026-03-07 14:34:44
Aptorum Group (NASDAQ: APM) received a Nasdaq notification for non-compliance with the $1 minimum bid price rule. The company has a 180-calendar-day grace period until September 1, 2026, to regain compliance and is exploring options, including a potential reverse stock split. The notification does not immediately impact the trading or listing of APM shares.
2026-02-26 16:51:36
This article provides an overview of Aptorum Group Ltd (APM) stock, highlighting its focus on developing therapeutic assets for oncology and infectious diseases, and its proposed merger with DiamiR Biosciences Corp. It also details recent corporate news, including clinical trial updates for its drug candidate ALS-4, financing activities, and efforts to maintain Nasdaq listing compliance.
